Toll Brothers
TOL
Meritage Homes
MTH
Taylor Morrison Home
TMHC
D.R. Horton
DHI
KB Home
KBH
US Stock MarketDetailed Quotes
MURA Mural Oncology
- 3.650
- +0.180+5.19%
Close Jan 8 16:00 ET
- 3.900
- +0.250+6.85%
Post 19:57 ET
62.27MMarket Cap-0.40P/E (TTM)
3.820High3.510Low528.19KVolume3.530Open3.470Pre Close1.95MTurnover4.16%Turnover RatioLossP/E (Static)17.06MShares5.62352wk High0.36P/B46.33MFloat Cap2.87052wk Low--Dividend TTM12.69MShs Float57.200Historical High--Div YieldTTM8.93%Amplitude2.870Historical Low3.694Avg Price1Lot Size
About Mural Oncology Company
Mural Oncology Plc is a clinical-stage oncology company, which engages in the business of discovering and developing immunotherapies for patients with cancer. Its lead product candidate is the Nemvaleukin Alfa which is an interleukin-2 cytokine designed to capture and expand therapeutic benefits of high-dose recombinant human IL-2. The company was founded on May 31, 2017 and is headquartered in Dublin, Ireland.
Company Profile
SymbolMURA
Company NameMural Oncology
Listing DateNov 6, 2023
Founded2017
CEODr. Caroline Loew, PhD
MarketNASDAQ
Employees117
Fiscal Year Ends12-31
Address10 Earlsfort Terrace
CityDublin
ProvinceDublin
CountryIreland
Zip Code2
Phone353-1-905-8020
Websitehttp://www.muraloncology.com
Company Executives
- Name
- Position
- Salary
- Dr. Caroline Loew, PhD
- Chief Executive Officer and Director
- 2.52M
- Vicki L. Goodman
- Chief Medical Officer
- 705.58K
- Adam D. Cutler
- Chief Financial Officer and Principal Accounting Officer
- 743.18K
- Maiken Keson-Brookes
- Chief Legal Officer
- --
- Scott T. Jackson, M.B.A.
- Chairman of the Board
- 65.97K
- Benjamin J. Hickey, M.B.A.
- Independent Director
- 51.79K
- Dr. George S. Golumbeski, PhD
- Independent Director
- --
- Dr. Francis M. Cuss, F.R.C.P.,M.B.
- Independent Director
- 58.63K
- Sachiyo Minegishi, M.B.A.
- Independent Director
- --
Trending US Stocks
Fed Rate Cut Beneficiaries Fed Rate Cut Beneficiaries
Stocks that are expected to benefit from a Federal Reserve rate cut. Information is provided by Futu and is a non-exhaustive list of all thematic stocks for reference purposes only.
This section presents the top 5 stocks in Fed Rate Cut Beneficiaries, ranked from highest to lowest based on real-time market data. Stocks that are expected to benefit from a Federal Reserve rate cut. Information is provided by Futu and is a non-exhaustive list of all thematic stocks for reference purposes only.
This section presents the top 5 stocks in Fed Rate Cut Beneficiaries, ranked from highest to lowest based on real-time market data.